Bedoya Armando, Pleasants Roy A, Boggan Joel C, Seaman Danielle, Reihman Anne, Howard Lauren, Kundich Robert, Welty-Wolf Karen, Tighe Robert M
Department of Medicine, Duke University, Durham, North Carolina, United States of America.
Division of Pulmonary Diseases and Critical Care Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
PLoS One. 2021 Mar 18;16(3):e0247316. doi: 10.1371/journal.pone.0247316. eCollection 2021.
The epidemiology of Interstitial Lung Diseases (ILD) in the Veterans Health Administration (VHA) is presently unknown.
Describe the incidence/prevalence, clinical characteristics, and outcomes of ILD patients within the Veteran's Administration Mid-Atlantic Health Care Network (VISN6).
A multi-center retrospective cohort study was performed of veterans receiving hospital or outpatient ILD care from January 1, 2008 to December 31st, 2015 in six VISN6 facilities. Patients were identified by at least one visit encounter with a 515, 516, or other ILD ICD-9 code. Demographic and clinical characteristics were summarized using median, 25th and 75th percentile for continuous variables and count/percentage for categorical variables. Characteristics and incidence/prevalence rates were summarized, and stratified by ILD ICD-9 code. Kaplan Meier curves were generated to define overall survival.
3293 subjects met the inclusion criteria. 879 subjects (26%) had no evidence of ILD following manual medical record review. Overall estimated prevalence in verified ILD subjects was 256 per 100,000 people with a mean incidence across the years of 70 per 100,000 person-years (0.07%). The prevalence and mean incidence when focusing on people with an ILD diagnostic code who had a HRCT scan or a bronchoscopic or surgical lung biopsy was 237 per 100,000 people (0.237%) and 63 per 100,000 person-years respectively (0.063%). The median survival was 76.9 months for 515 codes, 103.4 months for 516 codes, and 83.6 months for 516.31.
This retrospective cohort study defines high ILD incidence/prevalence within the VA. Therefore, ILD is an important VA health concern.
退伍军人健康管理局（VHA）中间质性肺疾病（ILD）的流行病学情况目前尚不清楚。
描述退伍军人管理局中大西洋医疗保健网络（VISN6）内ILD患者的发病率/患病率、临床特征和预后。
对2008年1月1日至2015年12月31日在VISN6的6个机构接受住院或门诊ILD治疗的退伍军人进行了一项多中心回顾性队列研究。通过至少一次就诊时出现515、516或其他ILD的ICD-9编码来确定患者。连续变量使用中位数、第25和第75百分位数进行总结，分类变量使用计数/百分比进行总结。对特征和发病率/患病率进行总结，并按ILD的ICD-9编码进行分层。生成Kaplan-Meier曲线以确定总体生存率。
3293名受试者符合纳入标准。经人工病历审查，879名受试者（26%）没有ILD证据。经核实的ILD受试者的总体估计患病率为每10万人256例，多年来的平均发病率为每10万人年70例（0.07%）。关注有HRCT扫描或支气管镜或手术肺活检的ILD诊断编码患者时，患病率和平均发病率分别为每10万人237例（0.237%）和每10万人年63例（0.063%）。515编码患者的中位生存期为76.9个月，516编码患者为103.4个月，516.31编码患者为83.6个月。
这项回顾性队列研究确定了退伍军人管理局内ILD的高发病率/患病率。因此，ILD是退伍军人管理局重要的健康问题。
